CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 50 of 113 entries

View as:

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Phase: N/A Priority: Normal

NCT ID: NCT02562859 Org: User:

Start: 09/30/15 End: 10/31/15 Due: 10/31/16

First-in-Human Single and Multiple Dose of GLPG1972

Phase: N/A Priority: Normal

NCT ID: NCT02612246 Org: User:

Start: 11/30/15 End: 07/31/16 Due: 07/31/17

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT03214614 Org: User:

Start: 11/14/16 End: 08/25/17 Due: 08/25/18

A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02623296 Org: User:

Start: 10/31/15 End: 02/29/16 Due: 02/28/17

Oral Bioavailability of Two Solid Formulations of GLPG0259.

Phase: N/A Priority: Normal

NCT ID: NCT01322451 Org: User:

Start: 11/30/10 End: 01/31/11 Due: 01/31/12

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase: N/A Priority: Normal

NCT ID: NCT04577781 Org: User:

Start: 10/12/20 End: 04/07/21 Due: 04/07/22

Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01820806 Org: User:

Start: 03/31/13 End: 04/30/13 Due: 04/30/14

GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study

Phase: N/A Priority: Normal

NCT ID: NCT01336244 Org: User:

Start: 04/30/11 End: 09/30/11 Due: 09/30/12

GLPG0259 Solid Formulation Bioavailability and Food Effect

Phase: N/A Priority: Normal

NCT ID: NCT01024517 Org: User:

Start: 11/30/09 End: 02/28/10 Due: 02/28/11

First-in-Human Single and Multiple Dose of GLPG1205

Phase: N/A Priority: Normal

NCT ID: NCT01887106 Org: User:

Start: 06/30/13 End: 10/31/13 Due: 10/31/14

Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution

Phase: N/A Priority: Normal

NCT ID: NCT03143725 Org: User:

Start: 04/14/17 End: 06/06/17 Due: 06/06/18

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT03410979 Org: User:

Start: 11/25/16 End: 08/15/17 Due: 08/15/18

A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02562950 Org: User:

Start: 09/30/15 End: 10/31/15 Due: 10/31/16

First-in-Human Single and Multiple Dose of GLPG1690

Phase: N/A Priority: Normal

NCT ID: NCT02179502 Org: User:

Start: 06/30/14 End: 12/31/14 Due: 12/31/15

GLPG0492 Pharmacodynamics

Phase: N/A Priority: Normal

NCT ID: NCT01538420 Org: User:

Start: 01/31/12 End: 04/30/12 Due: 04/30/13

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT03515382 Org: User:

Start: 03/16/18 End: 06/01/18 Due: 06/01/19

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal

NCT ID: NCT03864627 Org: User:

Start: 03/25/19 End: 02/27/20 Due: 02/27/21

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT03474042 Org: User:

Start: 11/29/17 End: 04/10/18 Due: 04/10/19

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT03798366 Org: User:

Start: 01/14/19 End: 06/22/20 Due: 06/22/21

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

Phase: N/A Priority: Normal

NCT ID: NCT03128606 Org: User:

Start: 03/28/17 End: 02/20/18 Due: 02/20/19

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01798979 Org: User:

Start: 02/28/13 End: 04/30/13 Due: 04/30/14

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

Phase: N/A Priority: Normal

NCT ID: NCT01888874 Org: User:

Start: 07/17/13 End: 05/14/15 Due: 05/14/16

A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal

NCT ID: NCT04700267 Org: User:

Start: 12/28/20 End: 10/06/21 Due: 10/06/22

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT03119649 Org: User:

Start: 03/18/17 End: 10/19/17 Due: 10/19/18

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01419990 Org: User:

Start: 08/31/11 End: 10/31/11 Due: 10/31/12

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food	NCT02562859	Galapagos NV	user2@example.com	None	2015-09-30	2015-10-31	2016-10-31	-	-	2025-07-14
First-in-Human Single and Multiple Dose of GLPG1972	NCT02612246	Galapagos NV	user2@example.com	None	2015-11-30	2016-07-31	2017-07-31	-	-	2025-07-14
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects	NCT03214614	Galapagos NV	user2@example.com	None	2016-11-14	2017-08-25	2018-08-25	-	-	2025-07-14
A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects	NCT02623296	Galapagos NV	user2@example.com	None	2015-10-31	2016-02-29	2017-02-28	-	-	2025-07-14
Oral Bioavailability of Two Solid Formulations of GLPG0259.	NCT01322451	Galapagos NV	user2@example.com	None	2010-11-30	2011-01-31	2012-01-31	-	-	2025-07-14
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	NCT04577781	Galapagos NV	user2@example.com	None	2020-10-12	2021-04-07	2022-04-07	-	-	2025-07-14
Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects	NCT01820806	Galapagos NV	user2@example.com	None	2013-03-31	2013-04-30	2014-04-30	-	-	2025-07-14
GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study	NCT01336244	Galapagos NV	user2@example.com	None	2011-04-30	2011-09-30	2012-09-30	-	-	2025-07-14
GLPG0259 Solid Formulation Bioavailability and Food Effect	NCT01024517	Galapagos NV	user2@example.com	None	2009-11-30	2010-02-28	2011-02-28	-	-	2025-07-14
First-in-Human Single and Multiple Dose of GLPG1205	NCT01887106	Galapagos NV	user2@example.com	None	2013-06-30	2013-10-31	2014-10-31	-	-	2025-07-14
Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution	NCT03143725	Galapagos NV	user2@example.com	None	2017-04-14	2017-06-06	2018-06-06	-	-	2025-07-14
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects	NCT03410979	Galapagos NV	user2@example.com	None	2016-11-25	2017-08-15	2018-08-15	-	-	2025-07-14
A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects	NCT02562950	Galapagos NV	user2@example.com	None	2015-09-30	2015-10-31	2016-10-31	-	-	2025-07-14
First-in-Human Single and Multiple Dose of GLPG1690	NCT02179502	Galapagos NV	user2@example.com	None	2014-06-30	2014-12-31	2015-12-31	-	-	2025-07-14
GLPG0492 Pharmacodynamics	NCT01538420	Galapagos NV	user2@example.com	None	2012-01-31	2012-04-30	2013-04-30	-	-	2025-07-14
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers	NCT03515382	Galapagos NV	user2@example.com	None	2018-03-16	2018-06-01	2019-06-01	-	-	2025-07-14
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis	NCT03864627	Galapagos NV	user2@example.com	None	2019-03-25	2020-02-27	2021-02-27	-	-	2025-07-14
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis	NCT03474042	Galapagos NV	user2@example.com	None	2017-11-29	2018-04-10	2019-04-10	-	-	2025-07-14
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis	NCT03798366	Galapagos NV	user2@example.com	None	2019-01-14	2020-06-22	2021-06-22	-	-	2025-07-14
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.	NCT03128606	Galapagos NV	user2@example.com	None	2017-03-28	2018-02-20	2019-02-20	-	-	2025-07-14
A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects	NCT01798979	Galapagos NV	user2@example.com	None	2013-02-28	2013-04-30	2014-04-30	-	-	2025-07-14
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)	NCT01888874	Galapagos NV	user2@example.com	None	2013-07-17	2015-05-14	2016-05-14	-	-	2025-07-14
A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus	NCT04700267	Galapagos NV	user2@example.com	None	2020-12-28	2021-10-06	2022-10-06	-	-	2025-07-14
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis	NCT03119649	Galapagos NV	user2@example.com	None	2017-03-18	2017-10-19	2018-10-19	-	-	2025-07-14
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects	NCT01419990	Galapagos NV	user2@example.com	None	2011-08-31	2011-10-31	2012-10-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance